Conjunctival Hemorrhagic Events Associated with Imatinib Mesylate

Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of hematology 2007-12, Vol.86 (5), p.390-393
Hauptverfasser:	RADAELLI, Franca, VENER, Claudia, RIPAMONTI, Francesco, IURLO, Alessandra, COLOMBI, Mariangela, ARTONI, Andrea, REDA, Gianluigi, LAMBERTENGHI DELILIERS, Giorgio
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Hematologic and hematopoietic diseases Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!